Daily Stock Analysis, FCSC, Fibrocell Science Inc, priceseries

Fibrocell Science Inc. Daily Stock Analysis
Stock Information
Open
1.89
Close
2.15
High
2.20
Low
1.89
Previous Close
1.96
Daily Price Gain
0.19
YTD High
2.20
YTD High Date
Feb 14, 2019
YTD Low
1.49
YTD Low Date
Jan 2, 2019
YTD Price Change
0.50
YTD Gain
30.30%
52 Week High
5.17
52 Week High Date
May 25, 2018
52 Week Low
1.45
52 Week Low Date
Dec 31, 2018
52 Week Price Change
-1.17
52 Week Gain
-35.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2017
10.21
Jan 17. 2017
12.08
8 Trading Days
18.39%
Link
LONG
Jun 6. 2017
11.60
Jul 7. 2017
19.30
22 Trading Days
66.34%
Link
LONG
Jun 20. 2018
2.48
Jun 27. 2018
2.64
5 Trading Days
6.55%
Link
LONG
Sep 24. 2018
2.31
Sep 25. 2018
2.46
1 Trading Days
6.28%
Link
Company Information
Stock Symbol
FCSC
Exchange
NasdaqCM
Company URL
http://www.fibrocellscience.com
Company Phone
484-713-6000
CEO
John M. Maslowski
Headquarters
Pennsylvania
Business Address
405 EAGLEVIEW BOULEVARD, EXTON, PA 19341
Sector
-
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0000357097
About

Fibrocell Science, Inc. operates as a autologous cell therapy company, which focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. Its clinical and pre-clinical programs include treatments for restrictive burn scars, vocal cord scars, and acne scars. The company was founded on September 1, 2009 and is headquartered in Exton, PA.

Description

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company's gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.